SecuritySKLN / Skyline Medical Inc. (83084T606)
CEO and PresidentKornberg Joshua
IndustryOrthopedic, Prosthetic, and Surgical Appliances and Supplies
Institutional Owners1
Institutional Shares57 - 0.00%
Common Shares Outstanding13,398,339 shares (as of 2018-06-30)
Related AIPT / Precision Therapeutics Inc.
SKLNU / Skyline Medical Inc.

Institutional Stock Ownership and Shareholders

SKLN / Skyline Medical Inc. Institutional Ownership

Skyline Medical Inc. (NASDAQ:SKLN) has 1 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 57 shares. Largest shareholders include BlackRock Fund Advisors.
Skyline Medical Inc. (NASDAQ:SKLN) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Prev Value
Current Value
2017-02-10 13F-HR BlackRock Fund Advisors 1,182 57 -95.18 0 0
SKLN: Skyline Medical Analysis and Research Report

2018-08-06 - Asif

Overview Skyline is a healthcare products and services company that is expanding its business to take advantage of emerging areas of the dynamic healthcare market through sales of its products, through its partnership with Helomics Holding Corporation (“Helomics”) and through pursuit of other strategic relationships to build value. The company's business highlights include: The company produce and sell the STREAMWAY®System, which the company consider to be the best solution to solve the issue of medical waste disposal, with a cost-effective and environmentally friendly technology which provides infection control associated with toxic waste management. Skyline has historically focused on growing the market for this product in the U.S. and are developing international markets. Skyline has acquired 25% of the capital stock of Helomics, a pioneering Contract Research Organization (“CRO”) Services company that bridges two significant areas of the healthcare industry:...

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

Precision Therapeutics Inc. (AIPT) CEO Carl Schwartz on Q2 2018 Results - Earnings Call Transcript

2018-08-15 seekingalpha
Good day, everyone, and welcome to the Precision Therapeutics Q2 2018 Business Update. Today's conference is being recorded. And at this time, I would like to turn the call over to Elizabeth Parker, Investor Relations at KCSA Strategic Communications. Please go ahead. (1-1)

Precision Therapeutics Investee, Helomics Corporation, Announces Commercial Launch of New 'HelomicsDiscover' Program to Drive Forward the Next Generation of Precision Cancer Therapies - MarketWatch

2018-08-14 marketwatch
Precision Therapeutics Inc. AIPT, +1.46% ("Precision" or "the Company"), a company focused on applying artificial intelligence to personalized medicine and drug discovery, is pleased to announce that Helomics Corporation, which has a definitive merger agreement with AIPT, has launched its new HelomicsDiscover(TM) program.

Precision Therapeutics' (AIPT) CEO Carl Schwartz on Q1 2018 Results - Earnings Call Transcript

2018-05-16 seekingalpha
Good day everyone, and welcome to the Precision Therapeutics Q1 2018 Business Update Conference Call. Today’s call is being recorded. At this time I would like to turn the call over to Todd Fromer. Please go ahead. (7-3)

Precision Therapeutics's (AIPT) CEO Carl Schwartz on Fiscal Year 2017 Results - Earnings Call Transcript

2018-04-03 seekingalpha
Precision Therapeutics Inc. (NASDAQ:AIPT) Fiscal Year 2017 Earnings Conference Call April 2, 2018 4:30 PM ET (4-3)

CUSIP: 83084T606